German generic drug company Stada in early talks over possible $11B sale, exec confirms

Spec­u­la­tion has been swirling in re­cent weeks over whether the Ger­man gener­ic drug com­pa­ny known as Sta­da might seek a sale worth about $11 bil­lion. CEO Pe­ter Gold­schmidt con­firmed the ru­mors to a Ger­man me­dia out­let on Tues­day but said he doesn’t ex­pect any­thing in the near term, a spokesper­son con­firmed.

Sta­da, bought by the in­vest­ment com­pa­ny Bain Cap­i­tal and the pri­vate eq­ui­ty firm Cin­ven for about $6 bil­lion in 2017, served up more strong quar­ter­ly growth, with the lat­est earn­ings up­date com­ing Tues­day. The com­pa­ny’s first half of the year showed strength, with sales up by 16% and earn­ings up by 30%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.